Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Bill Miller: Valeant shares could post 25-30 percent returns over five years

Published 09/13/2016, 04:41 PM
Updated 09/13/2016, 04:50 PM
© Reuters. Bill Miller, Chairman and Chief Investment Officer of Legg Mason Capital Development, leaves the morning presentation at the 26th annual Allen & Co conference in Sun Valley

NEW YORK (Reuters) - Noted value investor Bill Miller said on Tuesday that Valeant Pharmaceuticals International Inc (NYSE:VRX), the troubled Canadian drugmaker, is one of his top holdings, with the company's expected cash flows making the stock attractive.

Valeant's market value has fallen by some 90 percent in the last year as the company's drug pricing and other business practices prompted investigations by multiple U.S. government agencies and by Congress.

"We think with Valeant right now, it's a completely different company," Miller said at the CNBC Institutional Investor Delivering Alpha Conference in New York. "It's just a slow-growth specialty pharma company that will generate a lot of free cash and you should be able to make, I think, 25 to 30 percent on Valeant over the next five years."

Miller, the founder and chairman of LMM, said he sees no realistic probability of government action to control drug pricing, saying there are just "lots of hearings, lots of headline risk."

Valeant came under fire after it raised the price of two heart medications, Isuprel and Nitropress, by about 720 percent and 310 percent, respectively, after acquiring the drugs in 2015.

Miller estimated Valeant's free-cash flow yield at 25 to 30 percent. "The market believes the risk is super high and I just think the free cash flows will be there."

Valeant first came under scrutiny from New York prosecutors last October over its drug pricing and distribution. Media also reported at the time that it used pharmacy Philidor Rx Services to overcome insurer rejections to reimbursing its medications, with Philidor resubmitting claims to insurers until they were approved.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

On the broader stock market, Miller said his so-called best idea was to go long on the Standard & Poor's 500 and short on the 10-year Treasury note.

"You're talking a 6 percent rate of return on stocks versus 1.5 percent return on the 10-year Treasury," Miller said. "It strikes me that as I think (hedge fund investor) Paul Singer said, 'Treasuries are hardly a risk-free asset,' and I think the environment right now is the exact opposite of September 1987."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.